Aug 15 |
PainReform Provides Business Update for the Second Quarter of 2024
|
Aug 12 |
PainReform Announces Development and Successful Manufacturing of New Formulations Providing Anti-Inflammatory and Extended Analgesic Effects
|
Aug 7 |
PainReform Announces Favorable Safety Profile of PRF-110, Indicating Potential for Use in New Surgical Applications Requiring Higher Doses
|
Aug 5 |
PainReform Ltd. Announces Favorable Wound Healing Data in Human Clinical Trials for PRF-110
|
Aug 1 |
PainReform’s New Manufacturing Process Achieves Significant Benefits Including 18-Month Stability of PRF-110 at Room Temperature
|
Jul 24 |
PainReform files patent covering manufacturing process for post-operative pain control product
|
Jul 24 |
PainReform Files Patent Covering Highly Scalable Manufacturing Process for PRF-110 Following Successful Completion and Testing
|
Jun 26 |
PainReform Completes Enrollment in the Second Part of its Phase 3 Bunionectomy Trial for PRF-110
|
May 31 |
PainReform receives Nasdaq minimum bid price notification
|
May 31 |
PainReform Announces Receipt of Nasdaq Minimum Bid Price Notification
|